Thermo Fisher Scientific (TMO) PT Raised to $175 at Mizuho Securities

Mizuho Securities analyst Eric Criscuolo reiterated a Buy rating and raised its price target on Thermo Fisher Scientific (NYSE: TMO) to $175.00 (from $170.00) following solid Q2 results.

Criscuolo commented, "2Q was a solid quarter - clean but nothing fancy. Organic growth guidance was nudged up modestly. End markets continue along their trend lines. Biopharma and China are still driving growth, and should continue, despite strong comps. We continue to view TMO's unique product depth as a key competitive advantage and growth driver, as well as the nearly $3bn FCF generation that allows TMO to capitalize on management's established M&A track record, consolidate a fragmented industry, and consistently return cash to shareholders. Raising PT and reiterating our Buy rating."

For an analyst ratings summary and ratings history on Thermo Fisher Scientific click here. For more ratings news on Thermo Fisher Scientific click here.

Shares of Thermo Fisher Scientific closed at $158.90 yesterday.

You May Also Be Interested In

• MarineMax (HZO) PT Lowered to $35 at Stifel
• Parade Technologies Ltd. (4966:TT) PT Lowered to NT$870 at Nomura/Instinet
• Acrivon Therapeutics Inc (ACRV) PT Lowered to $22 at Jones Trading